Outcome | Artemisinin- naphthoquine (AN) | Dihydroartemisinin-piperaquine (DHP) | P | Overall |
---|---|---|---|---|
ACPR/Treatment Success (%, 95% CL) | ||||
ITT | 179 [89.1 (84.7–93.4)] | 180 [90.0 (85.8–94.2)] | 0.76 | 359 [89.5 (86.1–92.3)] |
Modified ITT | 179 [92.3 (88.5–96.0)] | 180 [94.7 (91.6–97.9)] | 0.33 | 359 [93.5 (90.5–95.7)] |
Per Protocol | 179 [93.7 (90.3–97.2)] | 180 [96.3 (93.5–99.0)] | 0.26 | 359 [95.0 (92.3–96.9)] |
Late Clinical Failure-LCF (%, 95% CL) | ||||
ITT | 5 [2.5 (0.3–4.6)] | 1 [0.5 (0.5–1.5)] | 0.10 | 6 [1.5 (0.6–3.2)] |
Modified ITT | 5 [2.6 (0.3–4.8)] | 1 [0.5 (0.5–1.6)] | 0.10 | 6 [1.6 (0.6–3.4)] |
Per Protocol | 5 [2.6 (0.4–4.9)] | 1 [0.5 (0.5–1.6)] | 0.10 | 6 [1.6 (0.6–3.4)] |
Late Parasitological Failure-LPF (%, 95% CL) | ||||
ITT | 7 [3.5 (0.9–6.0)] | 6 [3.0 (0.6–5.4)] | 0.78 | 13 [3.2 (1.7–5.5)] |
Modified ITT | 7 [3.6 (1.0–6.2)] | 6 [3.2 (0.7–5.6)] | 0.81 | 13 [3.4 (1.8–5.7)] |
Per Protocol | 7 [3.7 (1.0–6.3)] | 6 [3.2 (0.7–5.7)] | 0.81 | 13 [3.4 (1.8–5.8)] |
“Other Failures” (%, 95% CL) | ||||
ITT | 10 [5.0 (2.0–8.0)] | 13 [6.5 (3.1–9.9)] | 0.51 | 23 [5.7 (3.7–8.5)] |
Modified ITT | 3 [1.5 (0.2–3.3)] | 3 [1.6 (0.2–3.4)] | 0.98 | 6 [1.6 (0.6–3.4)] |
Per Protocol | 0 | 0 | 0 |